PLP2

Across TCGA pan-cancer cohorts, PLP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLP2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where PLP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.608	1.000	<.001	46	view →
LUAD	DFS	Median	II,III,IV	0.283	0.790	.009	15	view →
UCEC	DFS	Tertile	II,III,IV	0.431	1.000	.006	14	view →
COAD	DFS	Tertile	All	1.000	0.918	.047	12	view →
PDAC	DFS	Quartile	All	0.318	0.506	.015	9	view →
HNSC	DFS	Median	III,IV	0.317	0.767	.045	2	view →
LSCC	OS	Quartile	II,III,IV	0.834	0.997	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLP2–CCRCC (DFS)

Open the CCRCC breakdown →